Skip to content

AngioSculpt® Coronary Bifurcation Study

AngioSculpt® Scoring Balloon Catheter Multi-Center Coronary Bifurcation Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00686647
Acronym
AGILITY
Enrollment
93
Registered
2008-05-30
Start date
2008-04-30
Completion date
2011-01-31
Last updated
2011-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Myocardial Ischemia

Keywords

Coronary Angioplasty, Coronary Stents, Scoring Balloons, Coronary Artery Bifurcation Lesions

Brief summary

The purpose of this study is to evaluate a new angioplasty catheter, AngioSculpt® for the treatment of bifurcation lesions (blockages occurring at branch points) in coronary arteries.

Detailed description

Background: Bifurcation lesions, which consist of a narrowing occurring at branch points of coronary arteries, typically involve both the main branch (parent vessel) and an adjacent side branch. These lesions pose a particularly challenging situation for angioplasty procedures due to the difficulty of covering both branches with stents and a higher rate of recurrence (restenosis). A new angioplasty scoring balloon catheter (AngioSculpt®) has recently been approved for the treatment of narrowings in coronary arteries. The AngioSculpt® catheter incorporates a nitinol device that consists of spiral wires that wrap around the balloon catheter. As the balloon inflates, the spiral wires score the lesion allowing the balloon to be more stable (avoid slippage) and may enlarge the narrowed sections of the artery with less pressure or risk of dissection (uncontrolled tearing of the inner lining of the artery wall commonly seen with conventional balloons). Study Purpose: To demonstrate the safety and efficacy of the AngioSculpt® used in conjunction with coronary stents (implantable wire mesh tubes for scaffolding blocked arteries) for the treatment of coronary artery bifurcation narrowings and to compare these results with the historical outcomes associated with the use of conventional balloons and stents in the treatment of bifurcation lesions. Study Design: A prospective, multi-center, non-randomized, single-arm study with results compared to a literature search derived historical control for conventional balloon angioplasty (OPC - Objective Performance Criteria). The intent of this study is to enroll and treat 100 patients at 8 U.S. interventional cardiology programs with clinical follow-up planned at 30 days and 9 months following the procedure.

Interventions

DEVICEAngioSculpt® Scoring Balloon Catheter

Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion

DEVICEAngioSculpt Scoring Balloon Catheter

Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device

Sponsors

AngioScore, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years of age and able to give informed consent. * Patients with significant (\> 50% diameter stenosis) native coronary artery disease involving a bifurcation and the ostium of the side branch vessel (Medina class (x, x, 1)) including stable or unstable angina and silent ischemia. * Patients with lesions suitable for percutaneous coronary intervention (PCI).

Exclusion criteria

* Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices. * Additional planned coronary interventions for a non-target lesion within 9 months of the study procedure. * Left ventricular ejection fraction \< 35% * Patients refusing or not candidates for emergency coronary artery bypass grafting (CABG)surgery * Uncontrolled severe hypertension (systolic BP \>180 mm Hg or diastolic BP \>110 mm Hg) * Patients who are not candidates for chronic treatment with aspirin or Clopidogrel/Ticlopidine * Severe renal failure with creatinine \>2.0 mg/dL * Untreated pre-procedural hemoglobin \<10 g/dL * Coagulopathy manifested by platelet count \<100,000 or International Normalized ratio (INR) \>2.0 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment) * Women who are known or suspected to be pregnant * Patients in cardiogenic shock * Acute myocardial infarction (MI) within the past 72 hours, and/or elevated CPK (and abnormal Troponin-I) at the time of enrollment * Patients with a life expectancy of less than 1 year * Target main branch vessel \< 2.5 mm in diameter * Target main branch lesion \> 30 mm in length * Intended use of a bare metal stent (BMS) in the main branch * Target side branch vessel \< 2.0 mm in diameter * Target side branch lesion \> 15 mm in length * Target bifurcation angle \> 90º (distal angle) * Totally obstructed target coronary arteries (TIMI 0 or 1 flow) * Target bifurcation lesion within a previously placed stent (i.e. in-stent restenosis (ISR)) * Target bifurcation lesion within a surgical conduit (e.g. saphenous vein or internal mammary) * Target lesion demonstrating severe dissection prior to planned deployment of the AngioSculpt device * Unprotected Left Main diameter stenosis ≥ 50% * Visible thrombus (by angiography) at target lesion site * Coronary spasm in the absence of a significant stenosis * Patients who are concurrently participating in an investigational study when such participation could confound the treatment or outcomes of this study

Design outcomes

Primary

MeasureTime frameDescription
Procedural Success1 dayDefined as less than or equal to 30% diameter stenosis in the main branch and less than or equal to 70% diameter stenosis in the side branch at the conclusion of the procedure (including adjunctive stenting) in the absence of in-hospital major adverse cardiac events (MACE) \[cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR\]

Secondary

MeasureTime frameDescription
Major Adverse Cardiovascular Events30 dayscardiac death, myocardial infarction, or target lesion revascularization
Major Adverse Cardiac Events9 monthscardiac death, myocardial infarction, or target lesion revascularization

Countries

United States

Participant flow

Participants by arm

ArmCount
AngioSculpt Device93
Total93

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyDeath1
Overall StudyLost to Follow-up1

Baseline characteristics

CharacteristicAngioSculpt Device
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
36 Participants
Age, Categorical
Between 18 and 65 years
57 Participants
Age Continuous61.54 years
STANDARD_DEVIATION 11.6
Region of Enrollment
United States
93 participants
Sex: Female, Male
Female
26 Participants
Sex: Female, Male
Male
67 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
7 / 93
serious
Total, serious adverse events
2 / 93

Outcome results

Primary

Procedural Success

Defined as less than or equal to 30% diameter stenosis in the main branch and less than or equal to 70% diameter stenosis in the side branch at the conclusion of the procedure (including adjunctive stenting) in the absence of in-hospital major adverse cardiac events (MACE) \[cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR\]

Time frame: 1 day

Population: intention to treat

ArmMeasureValue (NUMBER)
Overall StudyProcedural Success91.4 percentage of participants
Secondary

Major Adverse Cardiac Events

cardiac death, myocardial infarction, or target lesion revascularization

Time frame: 9 months

ArmMeasureValue (NUMBER)
Overall StudyMajor Adverse Cardiac Events5.4 percentage of participants
Secondary

Major Adverse Cardiovascular Events

cardiac death, myocardial infarction, or target lesion revascularization

Time frame: 30 days

Population: intention to treat

ArmMeasureValue (NUMBER)
Overall StudyMajor Adverse Cardiovascular Events1.1 percentage of particpants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026